Novo Nordisk A/S
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novo Nordisk A/S sits in the top decile of US sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count).
Novo Nordisk A/S: 431 sponsored US clinical trials, 34 recruiting.
Novo Nordisk A/S sponsors 431 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 342 completed. 243 of these trials are in Phase 3-4 (later-stage) and 155 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 48 trials.
Top-decile sponsor footprint
Novo Nordisk A/S ranks in the top decile of sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
342 of 363 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
431 total, page 8 of 9
Effect of Renal Impairment on the Pharmacokinetics of NN9535
NCT00833716
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
NCT00789191
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
NCT00781937
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
NCT00773279
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
NCT00713648
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
NCT00700817
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
NCT01464099
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
NCT00710619
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
NCT01561950
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment
NCT01076842
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
NCT01261767
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
NCT00634842
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
NCT00620282
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
NCT00612040
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
NCT00611884
A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers
NCT01603342
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
NCT00665665
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
NCT00537303
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
NCT00523042
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00518882
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
NCT00503698
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
NCT00486278
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
NCT00427154
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
NCT01561937
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
NCT00411892
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
NCT00399711
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
NCT01516255
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
NCT01489644
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
NCT01490658
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
NCT00322257
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00333151
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
NCT00313001
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
NCT00294723
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
NCT01561924
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
NCT00264901
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
NCT02239146
Treatment of Congenital Factor VII Deficiency
NCT01779921
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
NCT00184548
Novofine Autocover Safety Needle Versus BD Safety Glide
NCT00121355
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
NCT00127296
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
NCT00115973
Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers
NCT01487811
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT00127283
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
NCT00108849
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
NCT00106366
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
NCT00104182
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NCT00097877
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
NCT00124293
INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00101751
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
NCT00097071
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 61 |
| Phase 3 | 220 |
| Phase 4 | 23 |
Therapeutic Areas
Where Novo Nordisk A/S enrollment is open (later-stage tilt)
34 recruiting of 431 indexed (8% open); 342 completed (79%).
Phase mix: 243 late (III/IV) vs 155 early (I/II) (later-stage heavy).
Top condition: Diabetes Mellitus, Type 2 (48 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novo Nordisk A/S: open-pipeline peers nationwide
Peers matched on 431 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 431 trials (± recruiting share)
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Dartmouth-Hitchcock Medical Center · 427 trials · 12% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Boston Scientific Corporation · 8% recruiting · 280 trials
- United Therapeutics · 8% recruiting · 63 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
Related
What to do with this Novo Nordisk A/S page
431 registered trials is a research-attention snapshot, not an endorsement of Novo Nordisk A/S or any single study.
- 34 of Novo Nordisk A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 2 is the condition Novo Nordisk A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novo Nordisk A/S pipeline card: 431 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.